You are here

Biologx

Help Us Achieve Our Goal of Bringing
More Affordable Insulin to US Patients

We intend to sell our insulin for $25-$50 per vial in the USA. With these reduced prices, our goal is to operate a profitable company while helping save lives for those who would otherwise not be able to afford insulin.

The companies that sell Insulin in the USA are making huge profits at the expense of patients’ lives lost.

Through Our Proprietary Technology,
Our Goal is to Bring Affordable Insulin to the Patient

Your investment will help us quickly bring our Insulin to market.*

Diabetes has been growing at an exponential rate, and your investment could help bring affordable insulin to the nearly 463 Million people living with diabetes


The Rising Price of Insulin Is Deadly

“Stories of Americans rationing insulin - and dying for it - have been making national headlines. The most famous case, perhaps, was 26-year-old Alec Smith, who died in 2017 less than a month after he aged out of his mother's health insurance plan. Despite working full-time making more than minimum wage, he could not afford to buy new insurance or pay the $1,000 a month for insulin without it. Biologx Insulin Price Chart

Reports suggest that insulin prices are influenced by the major pharmaceutical companies, and in some cases appear to have cost diabetic patients their lives. Insulin is a hormone produced by the pancreas and is critical for the regulation of glucose (sugar) in the blood. We are passionate about bringing affordable insulin to the market. Invest now to help us save lives.


BiologX Product Pipeline

We have an active pipeline of products in various stages of development: Biologx Product Pipeline

images

Real Stories From Diabetic Patients

“Boyle died because he was $50 short of reaching his $750 GoFundMe goal to pay for a month's supply of insulin”

– VICE, MAY 2017: The High Price of Insulin is Literally Killing People

“Nobody cared or nobody understood that without this next vial of insulin, I wouldn't live to see another week”

– Kristen Whitney Daniels: CBS NEWS, 2019

“Woman says her son couldn't afford his insulin – now he's dead”

– CBS NEWS: Mother Fights for Lower Insulin Prices After Son's Tragic Death

BiologX Proprietary Insulin Production Can Save Lives

When we set out to make high quality insulin affordable, we worked hard to eliminate inefficiencies throughout the production process. BiologX has devised unique processes for the production of recombinant human insulin (RHI) that enable us to make more insulin in a shorter period of time – all at affordable costs to patients worldwide. Our life-saving insulins meet or exceed USP Reference Standards, the highest quality standards in the market.*

The Result

BiologX intends to price our Insulin at rates that will be more affordable to patients - because we believe it’s essential to enable easy affordable access to Insulin and because we can make a reasonable profit while doing so.*
*BiologX's insulin product candidate has not yet been approved by the FDA.

full height

Why Invest in BiologX?

Save Lives | Solve Global Problem | Invest for Good
Market Value Global Insulin Market is projected to reach $27.71 billion by 2025.1
Growth Rate Compound Annual Growth Rate (CAGR) of 3.4% during the forecast period.1
Demand Increase An estimated 463.0 million adults (age 20–79) worldwide have diabetes. By 2030 a projected 578.4 million, and by 2045, 700.2 million adults will be living with diabetes.2
1Human Insulin Market Size, Share & Industry Analysis, By Type (Analogue Insulin (Long-Acting, Fast Acting, Premix), Traditional Human Insulin (Long-Acting, Short-Acting, Fast Acting, Premix)), By Diabetes Type (Type 1, Type 2), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019-2026, Fortune Business Insights
 
2IDF Diabetes Atlas, 9th ed., (2019)

Investment Opportunity

logo

Important Note on Stock Liquidity

Please note that BiologX intends to list its stock on an ATS (Alternative Trading System) at the completion of our Reg A+ offering.

An ATS is an after-market exchange where people that own securities can buy and sell them. Because all Reg A+ offerings are Public Offerings, listing Reg A+ securities after the Reg A+ completes on an ATS is a useful way for BiologX to provide liquidity to its investors. One big advantage of ATS exchanges is that shorting of stocks is not possible and naked shorting is also not possible. Please don't hesitate to reach out to us with any questions.


Meet The Team

team member

Ron Zimmerman

Co-Founder & Chief Science Officer

×

Ron Zimmerman

Co-Founder & Chief Science Officer

Ron has extensive experience leading specialty pharmaceutical companies. Prior to founding ZBP, he was the Founder & President of Elona Biotechnologies, Inc., a technology leader in proteomics, process development and characterization of therapeutic proteins. With offices, laboratories and production facilities located south of Indianapolis, the company was involved in the development and production of human insulin, insulin analogs, growth hormones, and other “follow-on” proteins to treat chronic diseases. Ron was also a founding member of the management team that grew Indiana Protein Technologies into a successful specialty pharmaceutical company and managed its acquisition by IVAX Corp (now part of Teva Pharmaceutical Industries Limited) in 2006. Ron spent a significant part of his career as Chief Scientist with Eli Lilly & Company for 28 years. He holds a Master of Science in Physiology & Biology and a Bachelor of Science in Physiology from Indiana State University. He is published in several peer-reviewed scientific publications and holds multiple patents in innovative production processes for both novel and bioequivalent protein products.

team member

David Wood

President & Chief Executive Officer

×

David Wood

President & Chief Executive Officer

David Wood brings 30+ years of expertise as a strategic and growth-oriented operations executive with a track record of building business, delivering revenue growth, and creating world-class operational structures to sustain growth and profitability. He has experience as President, COO, VP/General Manager and Board of Directors member for public and private companies. David served as Chief Restructuring Officer for Scient, Inc., a consulting company founded in 1997 where he had also served as VP/GM for the Enterprise Business Unit, building it to a $180 million business. Prior to that he was President & COO of an international consumer products company creating $400 million in shareholder value, validated by Credit Suisse First Boston during an expansion-financing round. Earlier in his career, David held various executive and operations roles with PepsiCo. Before entering the private sector, David was a Captain in the United States Army, Field Artillery. He holds a Bachelor of Science, Economics, Cum Laude, from Northeastern University.

team member

Dr. Donna Zimmerman

Vice President of Regulatory Affairs Nominee

×

Dr. Donna Zimmerman

Vice President of Regulatory Affairs Nominee

Dr. Zimmerman has 30+ years of experience at a senior level in the life sciences industry, in clinical and regulatory affairs, IND, NDA and regulatory submission, and clinical study management. Prior to co-founding ZBP, she was the CFO and Head of Clinical and Regulatory Affairs of Elona Biotechnologies, Inc. Dr. Zimmerman was also the Director, Clinical and Regulatory Affairs of Indian Protein Technologies, managing the financial aspects of the company until its acquisition by IVAX Corp (now part of Teva Pharmaceutical Industries Limited) in 2006. She founded and led a clinical trial management company, responsible for managing all aspects of clinical trials for multiple clients simultaneously. Dr. Zimmerman is a private pilot, holds a PhD in Health Research Administration from Kennedy Western University, a Master of Business Administration from Indiana Wesleyan University, a Bachelor of Science in Chemistry & Biology from the University of Indiana, and an Associate of Science in nursing from Colorado State University.

team member

Dr. Alexander Fleming

Chief Medical Officer Nominee

×

Dr. Alexander Fleming

Chief Medical Officer Nominee

Dr. Fleming received his M.D. in Internal Medicine training from Emory followed by fellowships at Vanderbilt and NIH. At the FDA, he led clinical reviews of biotech products including metformin, insulin analogs, statins, and human insulin. Dr. Fleming is also an author of multiple medical and scientific papers, and is a major contributor to FDA’s Good Review Practice (GRP) initiative.

Board of Advisors

Roger Harrison, PhD

Executive, Consultant

Robert L. Zied

Entrepreneur

David Wamsley

Finance Expert

Anthony Moravec

Entrepreneur

Rod Turner

Finance Expert


BiologX, Inc. was formed in November 2020. BiologX, Inc. has never had any common officers, directors, or shareholders with Sixty-Six Oil Field Services, Inc. (“SSOF”) and BiologX, Inc. is not related to SSOF in any way. Click here to read more.


Global Diabetes Impact

460M Diabetics Worldwide*
1 in 10 Americans*
Of AllU.S. Deaths*

References

*Unless otherwise indicated, facts and figures regarding demand, sales, and cost of insulin are referenced from the Centers for Disease Control and Prevention (CDC) and the International Diabetes Federation.

Are You Ready to Save Lives?

Help us bring our affordable insulin to market with an investment today.

Updates

August 19
What Do Pharmaceutical Companies Really Spend Their Profits On?

For decades, pharmaceutical companies have claimed that the skyrocketing price of insulin and other drugs is the direct result of innovation.
 
Earlier this year, the US House of Representatives began an investigation to determine just how much of pharmaceutical profits are spent on research and development. Their Drug Pricing Investigation report, which was released in July, tells a much different story than the one Big Pharma has been trying to sell us for years.

Buybacks and Dividends

According to the report, eight of the top 14 pharmaceutical companies in the world spend more on buybacks and dividends for their investors than they do on research and development (R&D). 

One of those eight companies, Novo Nordisk, spent more than twice as much on buybacks and dividends than they did on R&D every year between 2016 and 2020.

Overall, the 14 companies examined spent an average of 10% more on buybacks and dividends than they did on R&D. The US-based companies, which includes Eli Lilly, were the worst offenders, spending an average of 24% more on buybacks and dividends than on R&D.

Executive Compensation

Executive compensation packages made up another huge portion of the spending habits of the 14 companies evaluated in the investigation.

Altogether, these compensation packages totaled over $3.2 billion, with an average annual increase of 14% between 2016 and 2020. Most of these companies increased their executive compensation while also raising the prices of drugs that millions of Americans rely on.

Of the three insulin producers evaluated in the report, Eli Lilly paid out the most in executive compensation packages over the five-year period, with the other two companies trailing not far behind.

  • Eli Lilly - $234,000,000
  • Novo Nordisk - $129,000,000
  • Sanofi - $63,000,000

In some cases, the investigation found that bonuses paid out to executives were the direct result of price increases on brand-name drugs. Had these increases not been made, the companies would not have reached the profit goals necessary for the executives to obtain their bonus targets.

Research and Development

While all companies did invest a significant amount into research and development, the investigation found that much of this investment was used to suppress generic and biosimilar competition. This is in stark contrast to the claim that most expenditures made by pharmaceutical companies are used to foster innovation.

Securing extra patents and pursuing lawsuits are just some of the ways these companies spend their R&D money in order to continue their monopoly over certain types of drugs. In fact, more money is spent on patenting older products than on innovative products currently in development. 

What Does This Tell Us?

The US House of Representatives Drug Pricing Investigation makes clear that insulin prices are not skyrocketing due to innovation. And, in fact, investing in new products accounts for a very small percentage of the overall expenditures made by these companies.

Most of the profits these companies see go straight into buybacks and dividends. The rest is used to suppress competition within the market and pay astronomical compensation packages to reward executives for needlessly driving up the prices of life-saving drugs.

August 17
The Insulin Price Crises: What Is Patent Evergreening?

Patents are important for innovation. They act as a safeguard for inventors to help assure they receive adequate compensation for their work before competition enters the market. This time period varies by product but can last up to 20 years.

But patents can also be used to repress innovation and create monopolies. 

One of the most striking examples of this can be found in the insulin market. Here, big companies engage in a process called patent evergreening that allows them to safeguard their insulins for well over the maximum time period covered by any one patent.

According to an I-MAK investigational report, patent evergreening is a leading cause of today’s insulin pricing crises.

“Today, drugmakers are filing dozens or even hundreds of patents, resulting in nearly double the length of protection, blocking competition and keeping cheaper versions of medicines off the market. This abusive practice, known as ‘evergreening’, or what drugmakers market as incremental innovation and improvements, sits at the heart of the drug price crisis in the United States.” 

By making tiny changes to their insulin products, these big companies can apply for new patents to extend the protection period for their product indefinitely. 

In the insulin world, Lantus is one of the biggest offenders of patent evergreening. The product has been on the market since 2000 but is currently protected for 37 years thanks to new patents.

Sanofi, the company that owns Lantus, has filed for over 70 patents on the drug since 2000. Of those, the US government has granted 49—ensuring that Sanofi will have the undisputed power to set the price of this life-saving drug until at least 2037.

Considering that the price of Lantus jumped an astonishing 114% between 2012 and 2018, we can’t even imagine what it will cost by the time the patents run out. Assuming they ever do.

August 12
BiologX Share Price Change - Now $4.15 Per Share

Effective August 13, 2021 BiologX share price has changed from $4.10 per share to $4.15 per share. Please note that Regulation A permits us to increase our share price by up to 20% without amending our filing with the SEC.

August 12
Simple Breakdown: Why Is Insulin So Expensive?

The problems with the American healthcare system are complex and far-reaching. The same can be said about the issues that have driven up the cost of insulin to the point that 1 in 4 people living with diabetes are forced to ration the drug.

One of the best articles for explaining the high cost of insulin was published by Mayo Clinic Proceedings in 2019.

According to this article, there are six reasons insulin prices have risen by over 1000% in the last 20 years.

1. The customer base for insulin is a vulnerable population willing to pay any amount for this life-saving drug. This fact, combined with the complications that arise from other reasons listed here, most especially a lack of market competition, has led to greed that survives even as these vulnerable people die.

2. There is a virtual monopoly in the insulin market that has existed for decades. According to the article: Insulin pricing in the United States is the consequence of the exact opposite of a free market: extended monopoly on a lifesaving product in which prices can be increased at will, taking advantage of regulatory and legal restrictions on market entry and importation. Currently, there are only three companies authorized to sell insulin in the United States.

3. Patent abuse and evergreening. Every change, no matter how slight or inconsequential, that is made to an insulin formula results in patent extensions. Add to this the fact that analog insulins can be covered by multiple patents (Lantus currently has 70) and you end up with a drug that cannot be easily replicated and sold for less.

4. Barriers to biosimilar market entry. While this has improved in recent years thanks to congressional intervention and FDA support, getting biosimilar insulin to market has always been very difficult. The overuse of patents, frivolous lawsuits by large corporations, and difficulties obtaining coverage are the main reasons biosimilar drugs have historically not been pursued. 

5. PBMs and middlemen with considerable control over market prices. Pharmacy benefit managers are responsible for taking drugs and marketing them to wholesalers and pharmacies. These middlemen use their substantial power over the market and the conflicting interests of their many customers to drive up their cut of the profits. This results in huge increases in insulin prices over very short periods of time.

6. The lobbying power of pharmaceutical companies. The Big Three spend huge amounts of money on lobbying and advertising each year in order to thwart any attempts by the government to implement real solutions to the problems outlined above. Most recently, these companies have taken to creating “authorized generics” of their own products as a cheap PR move. Unfortunately, these more affordable products are intentionally not being widely distributed and make up a very small percentage of the insulin purchased each month.

August 10
What is “Authorized Generic” Insulin?

There is a new term floating around in the world of insulin production: authorized generic. If you read our article on biosimilars, then you already know there is no such thing as a generic when it comes to biologic pharmaceuticals like insulin. 

So that begs the question, what on earth is an authorized generic insulin?

The answer is definitely not what you would expect.

There are currently three insulins available in the United States that have been deemed authorized generics by the FDA, according to HealthLine

The first is insulin lispro, which is made by Eli Lilly as a lower priced version of Humalog. The problem? Insulin lispro IS Humalog. The two products are identical aside from the label and name.

The other two authorized generics are made by Novo Nordisk. Insulin aspart is the authorized generic of their top-seller, NovoLog. And insulin aspart mix is the generic of their 70/30 mix. Both products are identical to the insulins they were made to be the generic of.

So what is an authorized generic insulin? The exact same thing as the brand name but with a different label, different name, and (slightly) lower price tag.

This answer only creates a lot more questions. For one, if it is possible to make the same insulin using the same method and sell it for a lower price, why not just lower the price of the brand name insulin? And, more to the point, why would companies make a low-priced version of their top selling insulin?

The answer: because congress is demanding insulin prices be reduced. By responding to those demands by offering affordable insulin options, the big insulin companies can appease congress and avoid them taking more extreme measures such as passing price cap bills.

But, in truth, authorized generics are not an answer to anything. They are nothing more than a PR stunt.

The distribution and supply of these affordable insulins are controlled 100% by the companies that make them. And those companies have a vested interest in not letting their generics out-compete their identical, more expensive products. 

Analysis of prescription availability found that only 8% of Humalog prescriptions filled in 2019 were filled with generic insulin lispro and that the generic was not widely available or advertised in pharmacies across the country.

Meanwhile, the price of brand name insulins continues to rise and profits for the Big Three insulin makers continue to break records.

August 03
Price Hikes of Older Insulins are Driving the Insulin-Price Crisis

It makes sense to pay more for a newer, better drug. But why would anyone ever pay more than the rate of inflation for a decades-old drug that has no supply limitations?

If you’re buying insulin, odds are, you should be asking yourself that question.

recent study from the University of Pittsburgh found that the driving force behind skyrocketing insulin prices is being driven by price hiking of old insulins more so than the expected overpricing of newer insulins.

In one example given in the literature, the price of Lantus, made by Sonifi, increased by 49% in 2014—more than ten years after the drug was first released.

On average, old brand-named injectables see a price increase of 15% per year. Compared to inflation, which sits at between 1.5% and 2% on average, this is an incredible rate of change.

How are insulin companies able to get away with this? The author of the study, Inmaculada Hernandez, Ph.D., had an answer for that:

"These types of insulin have been around for a while. Whereas the original patent for Lantus expired in 2015, dozens of secondary patents prevent competition, and it is this lack of competition that allows manufacturers to keep increasing prices much faster than inflation."

The only way to stop these mega-pharmaceutical companies from pricing decades-old insulins right along with brand new products is to increase competition in the market. That is exactly what BiologX means to do.

Comments

Post comment

piptopia on August 26
How much are you looking to raise? When is the deadline?

mjabbar2 on August 09
Hi! I was also wondering about the current market cap, how much has been raised thus far, and what is the maximum for this raise? Thank you!

FREEDOM on August 09
Hey there would like to know how long is the process before I will see shares and interest also if I wanted to sell shares how do I go about it lol ?????

BiologX on August 09
Market Capitalization = the number of shares offered by the company * the current price per share. Upon the closing of the Reg A offering we intend to list our stock on an Alternative Trading System (ATS). An ATS is an SEC-regulated after-market exchange where people who own securities can buy and sell. Regulatory change in recent years has brought ATS into existence. Because all Reg A+ offerings are Public Offerings, listing Reg A+ securities after the Reg A+ completes on an ATS is a useful way for our company to provide liquidity to our investors. One big advantage of ATS exchanges is that shorting of stocks is not possible nor is naked shorting possible.

BiologX on August 09
Market Capitalization = the number of shares offered by the company * the current price per share.

Felicia Gooden on July 02
How is the offering of generic analogs by Walmart expected to impact Biologx strategy?

BiologX on July 03
It will have no impact on our strategy. When we introduce our insulin we’ll be happy to partner with Wal-Mart (and all pharmacies) so they can further lower the price of insulin. Because of our proprietary IP, we expect our manufacturing system to produce top tier insulin at significantly lower costs than existing producers, so we’ll be able to supply pharmacies at BiologX prices, not current prices.

Gary Hunt on July 03
Will I get update on stock value

BiologX on July 03
Yes you will. Updates will be posted on this site and all our sites as well. Also, please email us with any questions you might have at any time.

Offering Circular

Please read the Offering Circular here: Get Offering Circular

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM:

https://www.manhattanstreetcapital.com/offering-circular/25008

YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.